검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Bimekizumab |
Overview Company | UCB Biopharma SRL |
Overview Modality | ANTIBODY |
Overview Target | Hidradenitis Suppurativa |
Overview Indication | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | targeting of autoreactive T cell clonotypes shared among individuals with axSpA using depleting antibodies to the variable gene segment 9 of the T cell receptor |
MoA Biomarker | biomarkers and optimize therapeutic strategies |
PK/PD Half-life | 23 h |
PK/PD Species | 01) were elevated, including IBD, was detected. |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pd |
Toxicology Species | 01) were elevated, including IBD, was detected. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Disproportionality analysis of pyoderma gangrenosum reporting to the FDA Adverse Event Reporting System in association with antirheumatic biologics.. Several cases of pyoderma gangrenosum, a rare neutrophilic dermatosis, have been reported in patients initiating biological therapies for rheumatic health conditions. Despite this, systematic analysis across available therapies is lacking. This study… |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Bimekizumab |
Overview Company | UCB Biopharma SRL |
Overview Modality | ANTIBODY |
Overview Target | Hidradenitis Suppurativa |
Overview Indication | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | targeting of autoreactive T cell clonotypes shared among individuals with axSpA using depleting antibodies to the variable gene segment 9 of the T cell receptor |
MoA Biomarker | biomarkers and optimize therapeutic strategies |
PK/PD Half-life | 23 h |
PK/PD Species | 01) were elevated, including IBD, was detected. |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pd |
Toxicology Species | 01) were elevated, including IBD, was detected. |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Disproportionality analysis of pyoderma gangrenosum reporting to the FDA Adverse Event Reporting System in association with antirheumatic biologics.. Several cases of pyoderma gangrenosum, a rare neutrophilic dermatosis, have been reported in patients initiating biological therapies for rheumatic health conditions. Despite this, systematic analysis across available therapies is lacking. This study… |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교